Comtan Footer
For U.S. residents only Non-U.S. residents Novartis Pharma US
    Learn About Novartis
   
WHO SHOULD TAKE STALEVO?

 

 

 

 

STALEVO tablets, which contain carbidopa, levodopa, and entacapone are indicated for certain patients with Parkinson's disease.

If you are on levodopa therapy (carbidopa/levodopa) and experiencing symptom
re-emergence due to wearing-off, it may be time to ask about STALEVO. (NOTE: This is only for patients taking less than 600 mg of levodopa daily and not experiencing dyskinesia.)

If you are taking levodopa therapy and COMTAN® (entacapone) 200 mg tablets, you might be able to switch to STALEVO, a single tablet which contains all three medicines: carbidopa, levodopa and entacapone.

 
Why Should I Take It?
 
STALEVO does more than carbidopa/levodopa alone. It has been clinically proven to deliver more active time during the day—almost an hour and a half each day (1.4 hours). So you can enjoy more time with fewer symptoms.
 
 

People who take STALEVO may have more active time between doses, which may improve their daily activities.

STALEVO may improve activities of daily living. Activities of daily living include:

  • Speech
  • Walking
  • Handwriting
  • Dressing
  • Hygiene
 
     
  Find out how to talk to your healthcare provider.
 
  Find Out
 
     
Get a list of questions you can ask your healthcare provider.
 
Find Out
 
   
      Stalevo
 
 
Please see Important Safety Information.  
   
Orion Pharma  
Sinemet is a registered trademark of Merck & Co.
 
 
 
Novartis Use of website is governed by the Terms of Use and Privacy Statement.
Copyright ®2009 Novartis Pharmaceuticals Corporation. All rights reserved.